dc.contributor.author | Uysalol, Ezgi P. | |
dc.contributor.author | Özdemir, Gul N. | |
dc.contributor.author | Kiliç, Mehmet Akif | |
dc.contributor.author | Aydoǧan, Gönül | |
dc.contributor.author | Ayçiçek, Ali | |
dc.contributor.author | Bayram, Cengiz | |
dc.contributor.author | Tahtakesen, Tuba N. | |
dc.contributor.author | Gökçe, Müge | |
dc.date.accessioned | 2022-07-04T11:56:15Z | |
dc.date.available | 2022-07-04T11:56:15Z | |
dc.identifier.citation | Kiliç M. A. , Özdemir G. N. , Tahtakesen T. N. , Gökçe M., Uysalol E. P. , Bayram C., Ayçiçek A., Aydoǧan G., "Clinical Features and Outcome of Children with Hereditary Spherocytosis", Journal of Pediatric Hematology/Oncology, 2021 | |
dc.identifier.issn | 1077-4114 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_055de90e-54ed-4cbe-9bf5-f19437b57eae | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/181444 | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85107450404&origin=inward | |
dc.identifier.uri | https://doi.org/10.1097/mph.0000000000002211 | |
dc.description.abstract | © 2021 Thieme Medical Publishers, Inc.. All rights reserved.Objective: The aim of this study was to evaluate the demographics, clinical, and laboratory findings and treatment responses of patients with hereditary spherocytosis (HS). Materials and Methods: Data of children with HS were examined. Diagnosis was based on clinical history, physical examination, family history, presence of spherocytes on peripheral blood smear, and osmotic fragility test. Results: A total of 101 patients were included. The median (range) age at diagnosis was 38.0 (1 to 188) months. Mild, moderate, and severe forms of HS were present in 29 (28.7%), 15 (14.9%), and 57 (56.4%) patients, respectively. Family history was available in 73 patients and 56 of these (76.7%) had a positive family history for HS. Forty-five (44.5%) patients needed regular transfusions and all of these had severe disease. Although most patients did not require transfusion postsplenectomy, 2 of 45 (4.4%) patients continued to require transfusion. Transfusion dependence was significantly (P<0.001) higher in patients with severe spherocytosis. Conclusions: In HS, splenomegaly, pallor, and jaundice are the most common clinical features. Splenectomy dramatically reduces hemolysis in most cases and virtually abolishes further requirement for transfusion. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | HEMATOLOJİ | |
dc.subject | ONKOLOJİ | |
dc.subject | PEDİATRİ | |
dc.subject | Onkoloji | |
dc.subject | Pediatrics, Perinatology and Child Health | |
dc.subject | Health Sciences | |
dc.subject | Hematology | |
dc.subject | Oncology | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Çocuk Sağlığı ve Hastalıkları | |
dc.subject | İç Hastalıkları | |
dc.subject | Hematoloji | |
dc.title | Clinical Features and Outcome of Children with Hereditary Spherocytosis | |
dc.type | Makale | |
dc.relation.journal | Journal of Pediatric Hematology/Oncology | |
dc.contributor.department | Kanuni Sultan Süleyman Training and Research Hospital , , | |
dc.contributor.firstauthorID | 3395886 | |